Platinum-Sensitive Lung Small Cell Carcinoma — knowledge graph · CancerIndex

Knowledge graph · Cancer

Platinum-Sensitive Lung Small Cell Carcinoma

subtype

Identifier: CI-CAN-00008267
Entity page: /cancer/platinum-sensitive-lung-small-cell-carcinoma ↗
Edges: 10

Neighbours: 6 drugs4 trials
Drawn: 10 of 10 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,147 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Platinum-Sensitive Lung Small Cell Carcinoma investigated in trials for …INVESTIGATED_IN_TRIALSderived6 of 6
→ investigated in trials for	Topotecansmall molecule 2 trials (2 active) · roll-up of the cancer and its descendants	—	—	Platinum-Sensitive Lung Small Cell Carcinoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Berzosertibsmall molecule 1 trials (1 active) · roll-up of the cancer and its descendants

Platinum-Sensitive Lung Small Cell Carcinoma studied in …STUDIED_INderived4 of 4
→ studied in	NCT03896503Phase 2 · active not recruiting Randomized Trial of Topotecan With M6620, an ATR Kinase Inhibitor, in Small Cell Lung Cancers and Small Cell Cancers Outside of the Lungs · condition mapped ONTOLOGY_EXACT · 4 trials mapped (3 active)	—	—	Platinum-Sensitive Lung Small Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05353439Phase 1 · active not recruiting Testing of Tazemetostat in Combination With Topotecan and Pembrolizumab in Patients With Recurrent Small Cell Lung Cancer · condition mapped ONTOLOGY_EXACT · 4 trials mapped (3 active)	—	—	Platinum-Sensitive Lung Small Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04607954Phase 2 · active not recruiting Durvalumab and Lurbinectedin for the Treatment of Relapsed or Refractory Small Cell Lung Cancer · condition mapped ONTOLOGY_EXACT · 4 trials mapped (3 active)	—	—	Platinum-Sensitive Lung Small Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05572476Phase 2 · withdrawn Lurbinectedin Combined With Durvalumab in Pre-treated Patients With Extensive Stage Small-cell Lung Cancer · condition mapped ONTOLOGY_EXACT · 4 trials mapped (3 active)	—	—	Platinum-Sensitive Lung Small Cell Carcinoma	1	Observed	clinicaltrials	graph →